Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) TSE: AUP's stock price hit a new 52-week high on Wednesday . The company traded as high as $11.84 and last traded at $11.76, with a volume of 921800 shares trading hands. The stock had previously closed at $11.32.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on AUPH shares. Royal Bank Of Canada upped their price target on Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an "outperform" rating in a research report on Friday, August 1st. HC Wainwright reiterated a "buy" rating and issued a $17.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 30th.
Get Our Latest Stock Analysis on AUPH
Aurinia Pharmaceuticals Stock Up 6.1%
The company has a market cap of $1.58 billion, a P/E ratio of 27.93 and a beta of 1.23. The company has a current ratio of 5.23, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18. The firm's 50 day moving average price is $8.84 and its 200-day moving average price is $8.31.
Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its earnings results on Thursday, July 31st. The biotechnology company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.17 by ($0.01). The business had revenue of $70.01 million for the quarter, compared to the consensus estimate of $64.27 million. Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. As a group, equities research analysts expect that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current year.
Insider Buying and Selling at Aurinia Pharmaceuticals
In other news, Director Kevin Tang purchased 1,000,000 shares of Aurinia Pharmaceuticals stock in a transaction dated Friday, August 1st. The shares were bought at an average cost of $10.12 per share, with a total value of $10,120,000.00. Following the completion of the transaction, the director directly owned 11,029,500 shares in the company, valued at $111,618,540. This trade represents a 9.97% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have acquired 1,300,000 shares of company stock worth $13,590,000 over the last quarter. Company insiders own 12.20% of the company's stock.
Institutional Investors Weigh In On Aurinia Pharmaceuticals
Several large investors have recently made changes to their positions in the stock. Invesco Ltd. raised its stake in Aurinia Pharmaceuticals by 1.0% in the 4th quarter. Invesco Ltd. now owns 144,112 shares of the biotechnology company's stock valued at $1,294,000 after acquiring an additional 1,421 shares during the period. GAMMA Investing LLC boosted its stake in Aurinia Pharmaceuticals by 56.1% in the 1st quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock valued at $39,000 after purchasing an additional 1,744 shares during the period. Bridgefront Capital LLC boosted its stake in Aurinia Pharmaceuticals by 12.9% in the 4th quarter. Bridgefront Capital LLC now owns 16,606 shares of the biotechnology company's stock valued at $149,000 after purchasing an additional 1,891 shares during the period. Cetera Investment Advisers increased its holdings in shares of Aurinia Pharmaceuticals by 3.2% during the fourth quarter. Cetera Investment Advisers now owns 64,638 shares of the biotechnology company's stock worth $580,000 after purchasing an additional 2,000 shares during the period. Finally, Wealth Enhancement Advisory Services LLC increased its holdings in shares of Aurinia Pharmaceuticals by 20.8% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 12,989 shares of the biotechnology company's stock worth $110,000 after purchasing an additional 2,238 shares during the period. Institutional investors own 36.83% of the company's stock.
About Aurinia Pharmaceuticals
(
Get Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.